Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation

Blood

Volumn 101, Issue 5, 2003, Pages 2067-2069

  Vij, Ravi ^a   DiPersio, John F ^b   Venkatraman, Partha ^b   Trinkaus, Kathryn ^b   Goodnough, Lawrence T ^b   Brown, Randy A ^b   Khoury, Hanna J ^b   Devine, Steven M ^b   Oza, Aarti ^b   Shenoy, Shalini ^b   Blum, William ^b   Adkins, Douglas ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE;

ADOLESCENT; ADULT; AGED; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; BLOOD DONOR; BLOOD GROUP ABO SYSTEM; COHORT ANALYSIS; CYTOMEGALOVIRUS; DIAGNOSTIC ACCURACY; GRANULOCYTE TRANSFUSION; HUMAN; IMMUNOSTIMULATION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PERIPHERAL CIRCULATION; POPULATION RISK; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; SAFETY; SERODIAGNOSIS; STEM CELL TRANSPLANTATION; VIREMIA;

EID: 0037369342     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-07-2110     Document Type: Article

References (18)

1. Bensinger WI, Price TH, Dale DC, et al. The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood. 1993;81:1883-1888.
2. Strauss RG. Therapeutic granulocyte transfusions in 1993. Blood. 1993;81:1675-1678.
3. Adkins D, Goodnough LT, Moellering J, et al. Reduction in antibiotic utilization and in febrile days by transfusion of G-CSF mobilized prophylactic granulocyte components: a randomized study [abstract]. Blood. 1999;94:590a.
4. Blum W, Hallem C, Vij R, et al. Improved survival in allogeneic peripheral blood stem cell (PBSC) transplant patients who received prophylactic granulocyte transfusions from HLA-matched donors: long term follow-up [abstract]. Blood. 2001;98:58a.
5. Brytting M, Mousavi-Jazi M, Bostrom L, et al. Cytomegalovirus DNA in peripheral blood leukocytes and plasma from bone marrow transplant recipients. Transplantation. 1995;60:961-965.
6. Hamprecht K, Steinmassl M, Einsele L, Jahn G. Discordant detection of human cytomegalovirus DNA from peripheral blood mononuclear cells, granulocytes and plasma: correlation to viremia and HCMV infection. J Clin Virol. 1998;11:125-136.
7. von Laer D, SerrA, Meyer-Konig U, Kriste G, Hufert FT, Haller O. Human cytomegalovirus immediate early and late transcripts are expressed in all major leukocyte populations in vivo. J Infect Dis. 1995;172:365-370.
8. Yakushiji K, Gondo H, Kamezaki K, et al. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction. Bone Marrow Transplant. 2002;29:599-606.
9. Machado CM, Menezes RX, Macedo MC, et al. Extended antigenemia surveillance and late cytomegalovirus infection after allogeneic BMT. Bone Marrow Transplant. 2001;28:1053-1059.
10. Kanda Y, Mineishi S, Nakai K, Sait OT, Tanosaki R, Takaue Y. Frequent detection of rising cytomegalovirus antigenemia after allogeneic stem cell transplantation following a regimen containing antithymocyte globulin. Blood. 2001;97:3676-3677.
11. Junghanss C, Boeckh M, Carter RA, et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood. 2002;99:1978-1985.
12. Broers AE, van Der Holt R, van Esser JW, et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood. 2000;95:2240-2245.
13. America's Blood Centers. Granulocyte transfusions, Blood Bull. 2000;2. Available at: http://66.155.15.152/medical/bulletin_v2_n4.htm.
14. Hersman J, Meyers JD, Thomas ED, Buckner CD, Cliff R. The effect of granulocyte transfusions on the incidence of cytomegalovirus infection after allogeneic marrow transplantation. Ann Intern Med. 1982;96:149-152.
15. Winston DJ, Ho WG, Howell CL, et al. Cytomegalovirus infections associated with leukocyte transfusions. Ann Intern Med. 1980;93:671-675.
16. Adkins D, Goodnough LT, Shenoy S, et al. Effect of leukocyte compatibility on neutrophil increment after transfusion of granulocyte colony-stimulating factor-mobilized prophylactic granulocyte transfusions and on clinical outcomes after stem cell transplantation. Blood. 2000;95:3605-3612.
17. Narvios A, Pena E, Han XY, Lichtiger B. Cytomegalovirus infection in cancer patients receiving granulocyte transfusions. Blood. 2002;99:390-391.
18. Nichols WG, Price T, Boeckh M. Cytomegalovirus infections in cancer patients receiving granulocyte transfusions. Blood. 2002;99:3483-3484.